Frontier Pharma : Obesity - Identifying and Commercializing First-in-Class Innovation

AcuteMarketReports.com has announced the addition of " Frontier Pharma: Obesity - Identifying and Commercializing First-in-Class Innovation " Market Research Report to their Database.

Obesity is a major growing health concern around the world. In most markets, a person is considered obese if their Body Mass Index (BMI) exceeds 30 kilograms per square meter (kg/m2), calculated by dividing body mass in kilograms by height in meters squared. With the global prevalence continuing to rise, the disease has placed significant burden on healthcare expenditure, as it is also a major risk factor for cardiovascular diseases, diabetes and cancer.

View Full Report with TOC @ http://www.acutemarketreports.com/report/frontier-pharma-obesity-identifying-and-commercializing-first-in-class-innovation

Anti-obesity pharmacotherapy can be used as an adjunct lifestyle modification to improve weight loss in order to significantly reduce obesity-associated health risks in obese patients. However, the use of currently available anti-obesity drugs is largely limited by poor long-term safety and a modest weight loss effect. Despite substantial clinical and regulatory challenges, the early-stage obesity pipeline remains robust, containing a high level of first-in-class innovation that has the potential to be translated into effective and safe weight loss treatments.

List of Figures and Tables:

Table 1: The International Classification of Underweight, Overweight and Obesity in Adults 13

Table 2: Treatment Options Dependent on Body Mass Index 15

Figure 1: Innovation Trends in Product Approvals, 1987–2013 5

Figure 2: Sales Performance of First-in-Class and Non-First-in-Class Products Post Marketing Approval, 2006–2013 7

Figure 3: Molecular Targets of Marketed Products, 2015 19

Figure 4: Developmental Pipeline Overview 23

Figure 5: Players in the Obesity Pipeline 24

Figure 6: Developmental Pipeline Overview 25

Figure 7: Molecular Target Category Comparison, Pipeline and...